Apr 5, 2024 · 32m · american-optimist
Ep 83: A New Leukemia Cure with Ivan Dimov of Orca Bio · Joe Lonsdale
0:00 / 0:00
▶ Watch on YouTube →
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
In this episode of American Optimist, host Joe Lonsdale interviews Orca Bio CEO Ivan Dimov about how high-precision cell therapy and custom biomanufacturing are revolutionizing bone marrow transplants, curing blood cancers, and opening new frontiers for autoimmune diseases and longevity.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. Joe holds 24.4% of the talking time here. How this is scored →
Joe as informed peer 5.2 Guest teaching 4.4 Guest disagreement 0.3 Joe pushing back 0.6
speaking balance: gold is Joe, purple is the guest (3 minute bins)
Sharpest disagreement ▶ 12:43 Ivan defends regulatory rigor over speed
When Joe insists the FDA should immediately approve the therapy based on early successes, Ivan gently counters the premise by stressing that randomized trials are essential to unequivocally prove clinical superiority.
Hardest push from Joe ▶ 11:56 Joe challenges regulatory delay for proven curesJoe directly challenges institutional caution, arguing that delaying approval when survival data is already clear causes unnecessary deaths.
Biggest teaching moment ▶ 9:23 Ivan details the designer immune armyIvan clearly breaks down the fundamental science of immune composition, educating Joe on how selecting specific cell subsets eliminates graft rejection without dangerous synthetic manipulation.
Joe holds their own ▶ 23:27 Joe details Orca's microfluidic semiconductor sortingJoe demonstrates deep technical knowledge of Orca Bio's proprietary hardware by explaining semiconductor plate wells and scanning mechanisms before Ivan can describe them.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | Joe as informed peer | Guest teaching | Guest disagreement | Joe pushing back | Why |
|---|---|---|---|---|---|---|
| Introducing Ivan Dimov and His Academic Path | 4 | 3 | 0 | 0 | Joe introduces Ivan Dimov and establishes Orca Bio's mission, asking about his transition from electrical engineering and biophysics academia to entrepreneurship. Ivan explains the necessity of entrepreneurship to translate scientific breakthroughs to societal impact. | |
| The Genesis of Orca Bio at Stanford | 6 | 4 | 1 | 1 | Joe brings up government funding, academic research by Irv Weissman, and policy questions around drug development costs. Ivan explains the history of early cell therapy breakthroughs and why high-precision manufacturing necessitated spinning out into a private venture. | |
| How Cell Therapies Work as Living Medicines | 5 | 6 | 0 | 0 | Ivan educates Joe and the audience on why cell therapy functions as a living, self-manufacturing medicine and how Orca creates a designer immune system to eliminate lethal transplant rejection. | |
| Pioneering FDA Regulatory Pathways and Clinical Trials | 6 | 4 | 1 | 3 | Joe expresses frustration with regulatory bureaucracy and pushes the idea that the FDA should fast-track approval immediately based on 400 patient outcomes. Ivan diplomatically pushes back, emphasizing the necessity of randomized controlled trials to establish gold-standard clinical proof. | |
| The Moral Urgency and Ian's Miraculous Recovery Story | 4 | 5 | 0 | 0 | Joe calculates the monthly human cost of transplant mortality and prompts Ivan to recount the case study of Nate's father-in-law Ian, who made a rapid, complete recovery after Orca expanded trial age limits. | |
| Rebooting the Immune System for Autoimmune Diseases | 6 | 5 | 1 | 1 | Joe notes commercial dynamics, FTC headwinds under Lina Khan, and the unusual choice to commercialize independently. Ivan details how shrinking supply-chain timelines to 72 hours requires full vertical integration. | |
| Biomanufacturing Hardware, Laser Sorting, and Logistics | 7 | 5 | 0 | 0 | Joe demonstrates technical familiarity by citing semiconductor plates and well scanning. Ivan elaborates on utilizing laser-guided cell sorting and dedicated medical courier logistics. | |
| FDA Clearance for Multiple Sclerosis Trials and Manufacturing | 5 | 4 | 0 | 0 | Ivan reveals FDA clearance for clinical trials targeting primary progressive multiple sclerosis using Orca-Q, and discusses template manufacturing facilities. | |
| Predictions for 2030: Gene Editing and Lifesaving Scale | 4 | 4 | 0 | 0 | The conversation closes with long-range predictions for 2030, gene editing integration, and future tissue regeneration applications for longevity. |
Statements from this episode (13)
Novartis shut down Irv Weissman's promising breast cancer cell therapy program
“They had really incredible results in terminal breast cancer patients, and it was ultimately acquired by Sandoz slash Novartis, and everyone thought that was going to be delivered to patients, but You know, they shut down the whole program two years later, and…”
Cell therapies uniquely self-manufacture and expand within the patient's body
“And if you think of the cell as the actual active ingredient of the medicine, the actual medicine is a cell. What you're seeing there is that the, that, that the medicine is self manufacturing within your body and expanding, right? You could never do that with…”
Conventional bone marrow transplants kill 20 to 30 percent of patients
“Maybe 20, 30% of people will die from the medicine itself.”
Orca Bio clinical data shows practically zero transplant-related patient mortalities
“Well, we'll see, but the data so far suggests that we can bring it down to practically zero, right? Zero transplant related mortalities.”
Orca Bio has treated approximately 400 patients in clinical trials
“We treated about 400 or so folks with a couple of different products that we have in the clinic right now.”
Immune resets for leukemia patients have serendipitously eliminated MS and HIV
“There are sort of serendipitous situations where people have had, for example, really severe autoimmune diseases like multiple sclerosis, happen to also have leukemia on the side. For the leukemia, they get an immune system reset, and then they, you know, magi…”
Safe immune resets could eventually treat tens of millions of patients
“And I think the, you know, ultimately, if this keeps progressing the way that we've seen it so far, there's no reason why you couldn't be helping tens of millions of patients.”
Orca Bio must compress multi-year drug distribution cycles into 72 hours
“If you look at a regular medicine from the moment you get the raw material until you ship it to the factory, you build the pills and then you ship, you have the whole distribution network and all the warehousing until it gets to the hospital and ultimately get…”
Single-dose curative cell therapies disrupt healthcare payment models requiring upfront billing
“Because you have to condense all of the regular payments that you do when you take a pill. You might take a pill for many years. You have to condense them all into one payment because at the end of the day, this is a single dose curative medicine.”
Laser cell-sorting technology accelerates processing speeds by orders of magnitude
“So we have a whole stack of technologies that the technology you mentioned is sort of the accelerator to be able to broaden it out to really huge numbers of patients, where we're basically using lasers and light to move cells around and sort them, and, That ca…”
FDA clears Orca Bio for clinical trials treating multiple sclerosis
“We recently actually just got clearance from the FDA to begin clinical trials with multiple sclerosis patients with our second gen product, OrcaQ.”
No existing medication stops the progression of primary progressive multiple sclerosis
“There's really no medication that stops the progress there.”
Regenerative cell therapies will solve intractable degenerative diseases and expand human lifespan
“I mean, there's definitely stem cells for hair, and I know a few companies working on it, so we could probably regenerate that too, and I think you're going to see a lot of these totally intractable problems now start to be within the realm of being solvable, …”